ArticleWorld journal of radiology2026
Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers.
Article in World journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVedolizumab (VDZ) is a key biologic for moderate-to-severe ulcerative colitis (UC), but therapeutic response varies widely among patients. The combined predictive value of computed tomography (CT)-derived body composition (
aimTo develop a predictive model for VDZ response in moderate-to-severe UC patients, based on CT-derived body composition and nutritional/inflammatory markers, and to clarify their clinical implications.
methodsA retrospective study was conducted on UC patients treated with VDZ at the Affiliated Hospital of Qingdao University. CT images were analyzed to quantify intramuscular adipose tissue and skeletal muscle mass. Clinical data including CRP levels and hemoglobin (HB) were collected. Multivariate logistic regression was used to identify independent predictors of treatment response, and a predictive model was constructed.
resultsIMAT accumulation (odds ratio = 2.35, 95% confidence interval: 1.21-4.57,
conclusionThis study demonstrates that CT-derived body composition parameters (IMAT and skeletal muscle mass), combined with inflammatory markers (CRP) and HB levels, can effectively predict VDZ response in UC patients. The predictive model we developed offers a practical tool for identifying high-risk non-responders early, enabling clinicians to optimize individualized treatment strategies and improve clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.